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The CIAO (Coronary Interventions
Antiplatelet-based Only) Study
A Randomized Study Comparing
Standard Anticoagulation Regimen to Absence of
Anticoagulation for Elective Percutaneous Coronary Intervention
Eugenio Stabile, MD, PHD, FESC, FAHA,* Wail Nammas, MD,* Luigi Salemme, MD,*
Giovanni Sorropago, MD,* Angelo Cioppa, MD,* Tullio Tesorio, MD,* Vittorio Ambrosini, MD,*
Esther Campopiano, MD,* Gregory Popusoi, MD,* Giuseppe Biondi Zoccai, MD,† Paolo Rubino, MD*
Mercogliano and Turin, Italy
Objectives We sought to evaluate, in a double-blind, randomized, prospective study, safety and efficacy of elective percuta-
neous coronary intervention (PCI), with pharmacotherapy consisting of antiplatelet therapy and no anticoagula-
tion therapy.
Background Available guidelines recommend systemic anticoagulation agent use during PCI. Significant debate remains,
however, with regard to the correlation between the effects of systemic anticoagulation therapy and ensuing
ischemic and hemorrhagic complications.
Methods From June 2005 to January 2007, 700 patients undergoing elective PCI of an uncomplicated lesion have been
prospectively enrolled in the protocol. Patients should have been on aspirin and thienopyridine therapy and were
assigned either to the control arm (70 to 100 UI/kg unfractionated heparin) or to the no-heparin arm. A clinical
assessment was obtained before hospital discharge and at 30 days after PCI.
Results Procedural success was obtained in 100% of the cases. No acute or subacute thrombosis was observed. The
absence of anticoagulation therapy was associated with a significant decrease in post-procedural myocardial
damage (p  0.03) and bleeding events (p  0.048). At 30 days, the primary end point (death, myocardial in-
farction, or urgent target vessel revascularization) was more frequent in the control arm than in the no-heparin
arm (2.0% vs. 3.7%, respectively; absolute risk reduction 1.7% [95% confidence interval: 0.1% to 4.5%], p for
superiority  0.17, p for noninferiority 0.001).
Conclusions In the treatment of uncomplicated lesions and in the presence of dual antiplatelet therapy, elective PCI can be
safely performed without systemic anticoagulation and is associated with a reduced incidence of bleeding
complications. (J Am Coll Cardiol 2008;52:1293–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.026I
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eespite the development of new intravenous anticoagulant
gents that affect thrombin cascade, unfractionated heparin
UFH) remains the most commonly used agent during
ercutaneous coronary intervention (PCI). Significant de-
ate remains, however, with regard to the correlation
etween the effects of UFH and ensuing ischemic and
emorrhagic complications.
Currently available guidelines recently recommended
hat heparin should be administered in doses of 70 to 100
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ontevergine, Mercogliano, Italy; and †Interventional Cardiology, Division of
ardiology, S. Giovanni Battista-Molinette Hospital, University of Turin, Turin,
taly.w
Manuscript received March 26, 2008; revised manuscript received June 23, 2008,
ccepted July 11, 2008.U/kg and at a target activated clotting time (ACT)
etween 250 and 350 s, in the absence of a glycoprotein
Ib/IIIa inhibitor (GPI). Similarly, a target ACT of 200 s
hould be achieved when heparin is administered in
onjunction with a GPI (1,2).
See page 1299
A report from single-institution studies (3) and a multi-
enter registry (4) claimed that only minute doses of UFH
re needed during uncomplicated stent implantations. More
ecently, the use of GPI was advocated to perform coronary
tenting using minimal heparin dose (5). In a single-center
xperience (6), nonemergency PCI could be completed
ithout major adverse clinical events in patients receiving
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without scheduled anticoagula-
tion therapy. In the REMOVE
(Reduction in Major and Minor
Adverse Events With Eptifibatide-
based Pharmacotherapy in Percu-
taneous Coronary Intervention)
trial (7), antiplatelet therapy in-
cluding aspirin, clopidogrel, and
GPI without anticoagulation ther-
apy appears to decrease bleeding
complications after elective PCI.
The ESPRIT (Enhanced Sup-
pression of the Platelet IIb/IIIa
Receptor with Integrilin Ther-
py) trial showed that the degree of heparin anticoagu-
ation, as measured by ACT, did not significantly affect
he rate of ischemic events. Ischemic complications in
his study did not increase at the lowest levels of ACT,
hereas bleedings were reduced for the placebo group at
ower ACT levels (8).
It has been suggested (9) that in the future, to make a safe
rocedure even safer, comparisons of UFH even with no
ntithrombin therapy should continue to focus on reducing
he risk of bleeding during PCI. In this study, we evaluated
n a double-blind, randomized, prospective study, the safety
nd efficacy of elective PCI of uncomplicated lesions, with
djunctive pharmacotherapy consisting of antiplatelet ther-
py alone, without scheduled unfractionated heparin or
ther antithrombin therapy.
ethods
atient selection. From June 2005 to January 2007, all
atients undergoing elective PCI for treatment of chronic
oronary artery disease were screened for enrollment and
sked to consent to trial inclusion if a coronary angiogram
howed the presence of a single target lesion meeting the
ollowing inclusion criteria: 1) located in a native coronary
rtery segment 2.5 mm in diameter; 2) 70% diameter
tenosis; 3) 33 mm in length; 4) noncalcified; 5) without
mportant side branches (2.5 mm); 6) nonostial or left
ain; 7) free of visible thrombus; and 8) no chronic
cclusion.
Patients were excluded from the study if they had the
ollowing: 1) acute coronary syndromes; 2) recent myocar-
ial infarction (2 weeks); 3) refused to sign informed
onsent before enrollment; 4) 90 years old; 5) received
nfractionated heparin within 12 h, low molecular weight
eparin within 24 h, or warfarin within 3 days; 6) an
nternational normalized ratio 1.3; 7) an indication for
ong-term anticoagulation; and 8) contraindication to aspi-
in and/or thienopyridines.
The protocol was approved by the hospital Institutional
Abbreviations
and Acronyms
ACT  activated clotting
time
CABG  coronary artery
bypass graft surgery
CK-MB  creatine kinase-
myocardial band
GPI  glycoprotein IIb/IIIa
inhibitor
PCI  percutaneous
coronary intervention
UFH  unfractionated
heparineview Board and the local ethics committee. intiplatelet therapy. All eligible patients were taking
spirin (75 to 160 mg/day) and should have been on
iclopidine therapy (250 mg twice daily) or clopidogrel (75
g/day) for at least 7 days. Alternatively, patients received
lopidogrel preload (300 mg) 24 h before procedure. Use of
PI was allowed at the operator’s discretion.
tudy design. Seven hundred patients were enrolled and
andomly assigned to control (70 to 100 UI/kg UFH
dministered before guiding catheter insertion, with the
ntention of achieving ACT 250 s; additional heparin
ould be administered at the operator’s discretion) (1,2) or
o placebo (saline before guiding catheter insertion, same
olume amount of hypothetical heparin dose).
Interventional physicians were blinded to the ACT re-
ults (obtained by Medtronic ACT II, Minneapolis, Min-
esota); an unblinded nurse monitored ACT every 5 min
fter heparin bolus administration and gave heparin or
aline according to the study arm and ACT values. Cathe-
ers were flushed with UFH saline (7.5 UI/ ml). No more
han 100 ml flushes were allowed per procedure. Contrast
gent was uniformly nonionic (Iobitridol, Guerbet, Roissy,
rance).
ngiographic assessment. Patient, lesion characteristics,
nd percutaneous transluminal angiography results were
ssessed independently by 2 physicians (assisted by edge-
etection software provided with the Phillips-Integris Unit,
indhoven, the Netherlands). Lesions were categorized
ccording to the modified American Heart Association/
merican College of Cardiology classification (10).
ost-procedural patient management. Femoral sheaths
ere manually removed as early as “holding area” staff was
eady and independently from ACT values. An electrocar-
iogram was obtained before the procedure, immediately
fter the procedure, and before discharge. Serum creatine
inase-myocardial band (CK-MB) and a complete blood
ount were tested before PCI, and at 6, 12, and 24 h after
he procedure. Before discharge, a physician evaluated all
atients, with special emphasis on arterial access site.
ollow up. All patients were followed up at 30 days by
linical examination and a structured questionnaire.
tudy end points. Any clinical event has been adjudicated
y a committee consensus composed by 3 physicians not
nvolved in patient management and blinded to study
roups. Procedural success was considered a 30% residual
tenosis and Thrombolysis In Myocardial Infarction
TIMI) flow grade 3 achieved. Clinical success was consid-
red when procedural success was attained without any
arget vessel related death, acute myocardial infarction,
mergency coronary artery bypass graft surgery (CABG),
troke, or urgent vessel revascularization within 7 days of the
rocedure. The primary end point was defined as the
omposite of death, acute myocardial infarction, or need for
rgent vessel revascularization occurring within 30 days of
he index procedure.
Acute myocardial infarction (MI) was defined as: 1) an
ncrease in CK-MB 3 times the upper limit of normal in
2
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October 14, 2008:1293–8 Elective PCI Without Systemic Anticoagulationseparate blood samples, or if CK-MB was elevated before
he procedure, an increase in CK-MB 3 times the upper
imit of normal associated with an increase of 50% above
he last pre-procedural level; or 2) new Q waves (0.04 m/s)
n 2 contiguous electrocardiography leads. Urgent TVR
as defined as repeat PCI of the target vessel or bypass
urgery within 30 days.
Secondary end points included bleeding complications,
lassified according to the TIMI study, GUSTO (Global
tilization of Streptokinase and Tissue-Type Plasmino-
en Activator for Occluded Coronary Arteries) study,
TEEPLE (Safety and Efficacy of Enoxaparin in Percu-
aneous Coronary Intervention Patients) trial, and ACU-
TY (Acute Catheterization and Urgent Intervention
riage Strategy Trial) criteria.
For TIMI (11), major criteria included intracranial hem-
rrhage or clinical bleeding associated with a hemoglobin
rop of5 g/dl (or hematocrit decrease by15 points or by
0 to 15 points with clinical bleeding) and minor criteria
ncluded a hemoglobin drop of 3 g/dl (or hematocrit
ecrease 10 points) with clinical bleeding or 4 g/dl (or
ematocrit decrease by 10 to 15 point) with no clinical
leeding. Clinical bleeding was defined as: 1) a large
ematoma; 2) gastrointestinal blood loss; or 3) retroperito-
eal bleeding.
For GUSTO criteria (12), mild was defined as non–
ABG-related bleeding up to 48 h with no need for
ransfusion and no hemodynamic compromise. Moderate
as defined as non–CABG-related bleeding up to 48 h with
ransfusion required; and severe or life-threatening was
on–CABG-related bleeding up to 48 h with hemodynamic
ompromise.
For STEEPLE criteria (13), major was defined as bleed-
ng that met at least 1 of the following: fatal bleeding;
etroperitoneal, intracranial, intraocular bleeding; bleeding
hat causes hemodynamic compromise requiring specific
reatment; bleeding that requires intervention (surgical or
ndoscopic) or decompression of a closed space to stop or
ontrol the event; clinically overt bleeding; requirement for
ny transfusion of 1 U packed red cells or whole blood;
nd clinically overt bleeding causing a decrease in hemoglo-
in of 3 g/dl (or if hemoglobin level not available, a
ecrease in hematocrit of 10%). Minor was defined as
leeding that did not meet any of the criteria of major
leeding and that met at least 1 of the following: gross
ematuria not associated with trauma; epistaxis that is
rolonged, repeated, or requires plugging or intervention;
astrointestinal hemorrhage; hemoptysis; subconjunctival
emorrhage; hematoma 5 cm or leading to prolonged or
ew hospitalization; clinically overt bleeding causing a
ecrease in hemoglobin of 2 to 3 g/dl; and uncontrolled
leeding requiring protamine sulphate administration.
For ACUITY criteria (14), major bleeding was defined as
ntracranial bleeding; intraocular bleeding; access site hem-
rrhage requiring intervention; 5 cm diameter hematoma;
eduction in hemoglobin concentration of 4 g/dl without In overt source of bleeding; reduction in hemoglobin
oncentration of 3 g/dl with an overt source of bleeding;
eoperation for bleeding; and use of any blood product for
ransfusion.
tatistics. Sample size was computed according to a non-
nferiority design, assuming a 2.5% event rate for the
rimary end point in the conventional treatment group,
iming for alpha  5%, beta  20%, and choosing as the
bsolute upper noninferiority boundary, not the relative
oundary, a margin of tolerance 5.5%, thus yielding 350
atients per group. Continuous variables between groups
ere compared by the t test for normally distributed values.
roportions were compared by the chi-square test or the
isher exact test, where appropriate. Absolute risk differ-
nces (with 95% confidence intervals [CIs]) were also
omputed with CI analysis (15). Results are expressed as
ean  SD or n (%) unless otherwise specified. A 2-tailed
robability value 0.05 was considered statistically signifi-
ant for superiority analysis, and a 1-tailed probability value
0.05 was considered statistically significant for noninferi-
rity analysis.
esults
total of 700 patients (350/group) were enrolled. Baseline
emographic characteristics are listed in Table 1; baseline
esion and procedural characteristics are listed in Table 2.
reatment groups resulted in being matched with regard to
aseline clinical, lesion complexity, and procedural charac-
eristics (Table 2).
The median ACT at the end of PCI was 201  34 s in
he control group and 127  25 s in patients receiving no
cheduled anticoagulation. Bailout heparin or GPIs were
ever used. Seventy percent of the patients in each group
eceived a clopidogrel preload the day before the interven-
ion; the remaining patients were chronically on thienopy-
aseline Characteristics of Patients
Table 1 Baseline Characteristics of Patients
Characteristics
Control
(n  350)
No Heparin
(n  350)
p
Value
Age (yrs), mean SD 62.9 10.6 62.9 10.7 NS
Male gender, n (%) 274 (78.2) 276 (78.8) NS
Hypercholesterolemia, n (%) 198 (56.6) 209 (59.7) NS
Smoking history, n (%) 183 (52.4) 188 (53.7) NS
Creatinine clearance (ml/min), n (%)
30–60 52 (14.8) 48 (13.7) NS
30 4 (1.1) 4 (1.1) NS
Diabetes mellitus, n (%) 123 (35.2) 93 (26.5) NS
IDDM 16 (4.6) 18 (5.1) NS
NIDDM 107 (30.6) 75 (21.4) 0.05
Ejection fraction, mean SD 53.4 4.8 53.4 4.5 NS
Long-term treatment with
thienopyridine, n (%)
109 (31.1) 103 (29.5) NS
Ticlopidine 4 (1.1) 1 (0.3) NS
Clopidogrel 105 (30) 102 (29.2) NS
Clopidogrel preload, n (%) 241 (68.9) 247 (70.5) NSDDM  insulin-dependent diabetes mellitus; NIDDM  non–insulin-dependent diabetes mellitus.
r
n
l
s
d
d
l
t
w
a
c
a
e
e
i
l
w
s
n
w
i
s
i
v
p
t
3
4

p
n
l
g
s
b
m
b
o
c
D
T
u
e
p
P
E
P
t
Q
M
Aa
V
u
1296 Stabile et al. JACC Vol. 52, No. 16, 2008
Elective PCI Without Systemic Anticoagulation October 14, 2008:1293–8idine therapy at the time of PCI. The reduced ACT in the
o-heparin group resulted in safe early sheath removal and
imited time of access site compression.
Quantitative coronary angiography analysis (Table 3)
howed similar data between the groups.
Intraprocedural angiographic complications (Table 4)
id not result in increased post-procedural myocardial
rocedural Characteristics
Table 2 Procedural Characteristics
Characteristics
Control
(n  350)
No Heparin
(n  350)
p
Value
Lesion type, n (%)
A 75 (21.4) 96 (27.4) NS
B1 136 (38.9) 114 (32.5) NS
B2 106 (30.3) 105 (30.1) NS
C 33 (9.4) 35 (10.0) NS
Lesion length, mm (mean SD) 14.4 5.9 15.3 6.8 NS
Target vessel, n (%)
LAD 112 (32) 123 (35.1) NS
LCX 114 (32.6) 128 (36.7) NS
RCA 124 (35.4) 99 (28.2) NS
No. diseased vessels/patient, mean SD 1.6 1.4 1.6 0.72 NS
Femoral sheath, n (%)
5-F 337 (96.3) 336 (96) NS
6-F 13 (3.7) 14 (4) NS
Heparin no./total number, n (%) 350 (100) 0 (0) 0.05
Glycoprotein IIb/IIIa inhibitor n/total
number, n (%)
0 (0) 0 (0) NS
Peak activated clotting time (s),
mean SD
201 34 127 25 0.05
Drug-eluting stents (%), n (%) 195 (55.7) 188 (53.8)
SES 52.7 40.5 NS
PES 37.2 44.7 NS
EES 9.5 11.7 NS
TES 1.6 3.1 NS
Average number of stents used per lesion 1.10 1.08 NS
Multiple stent procedures, n (%) 30 (8.6) 26 (7.4) NS
Guiding catheter or wire thrombosis, n (%) 0 (0) 0 (0) NS
Procedure time (min), mean SD 11.5 6.6 10.7 7.1 NS
Closure devices used, n (%) 0 (0) 0 (0) NS
Duration of manual compression (min),
mean SD
13.1 4.9 5.4 2.4 0.05
ES everolimus-eluting stent; LAD left anterior descending artery; LCX left circumflex artery;
ES  paclitaxel-eluting stent; RCA  right coronary artery; SES  sirolimus-eluting stent; TES 
acrolimus-eluting stent.
uantitative Coronary Angiography Analysis
Table 3 Quantitative Coronary Angiography Analysis
Characteristics
Control
(n  350)
No Heparin
(n  350) p Value
Pre-procedural
RVD 2.92 0.52 2.96 0.47 NS
MLD 0.74 0.21 0.73 0.25 NS
% stenosis 74 5.9 75 7.8 NS
Post-procedural
RVD 3.07 0.49 2.96 0.47 NS
MLD 2.75 0.51 2.70 0.49 NS
% stenosis 10.8 8.6 11.9 8.7 NSpLDminimal lumen diameter; RVD reference vessel diameter; % stenosis 1 (MLD/RVD).amage. No intracoronary thrombosis was observed; a
imited number of procedures, without difference among
he groups, required more than 1 stent to be placed; this
as done (Table 4) in most of the cases of plaque shift
nd only in a limited number of cases of flow-limiting
oronary dissection.
The primary end point of the study of noninferiority was
lready reached for the placebo group after 350 patients
nrolled for each group. In-hospital major adverse cardiac
vents are listed in Table 5. Within 30 days, no death occurred
n either group. Two patients required urgent vessel revascu-
arization in the control group; both the patients presented
ith a flow-limiting dissection that required new stent appo-
ition within 2 h from the index procedure; 1 patient in the
o-heparin group presented on day 4 to a peripheral hospital
ith chest pain. In this case, a coronary angiography showed
ncomplete expansion of a mid left anterior descending artery
tent that required new balloon dilation.
The periprocedural myocardial infarction rate was signif-
cantly higher in the heparin versus the placebo group (3.1%
s. 1.7%; p  0.05) (Fig. 1). At 30 days, the primary end
oint was more frequent in the standard anticoagulation
han in the no-anticoagulation group (respectively, 2.0% vs.
.7%, absolute risk reduction 1.7% [95% CI: 0.1% to
.5%], p for superiority  0.17, p for noninferiority
0.001) (Table 4). Of note, no patients experienced a
ost-procedural Q-wave acute myocardial infarction.
Bleeding incidence is reported in Table 6. A very limited
umber of bleeding events occurred in the study; neverthe-
ess, a reduced overall incidence of bleeding in the placebo
roup was observed. No transfusions were required. The
tatistical value of this observation varied according to the
leeding classification used. The rates of TIMI (major or
inor) and ACUITY and GUSTO bleedings were minimal
ut not significantly different between the groups. The rate
f STEEPLE bleedings (major and minor) were signifi-
antly reduced in the group receiving placebo.
iscussion
he results of this study demonstrate that elective PCI of
ncomplicated coronary lesions can be safely conducted
ven in the absence of systemic anticoagulation. This
rocedure is not associated with an increased ratio of
ngiographic Complicationsd Subsequent Non–Q-Wave MI
Table 4 Angiographic Complicationsand Subsequent Non–Q-Wave MI
Angiographic
Complications
Control
(n  350)
Non–Q-Wave
MI
No Heparin
(n  350)
Non–Q-Wave
MI
p
Value
Visible thrombus 0 (0) 0 (0) 0 (0) 0 (0) NS
Dissection 8 (2.3) 0 (0) 6 (1.7) 0 (0) NS
Plaque shift 22 (6.3) 1 (4.5) 20 (5.7) 0 (0) NS
No reflow 0 (0) 0 (0) 0 (0) 0 (0) NS
alues are n (%). Number of non–Q-wave MI  post-procedural creatine kinase release 3 times
pper limits of normal.
MI  myocardial infarction.eriprocedural ischemic events when compared with stan-
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ssociated with a reduced incidence of bleeding events.
Recently published guidelines provide a class I recom-
endation to administer UFH to patients undergoing PCI
ith a Level of Evidence C (2). This level of evidence is
ased only on the consensus opinion of experts, case studies,
r standard of care. As stated by the scientific societies
ndorsing the guidelines, a recommendation with a Level of
vidence C does not imply that the recommendation is
eak but that randomized trials are not available (2).
The purpose of this study was to provide a randomized
linical study testing the safety and efficacy of simple lesion
lective PCI in the absence of systemic anticoagulation. In
ur study, the absence of systemic anticoagulation was shown
o be noninferior to standard therapy in terms of post-
rocedural ischemic events. Despite following guidelines-
ecommended heparin doses in the control group, only a
Figure 1 Post-Procedural Myocardial Damage
Creatine kinase-myocardial band (CK-MB) release after percutaneous coronary
intervention (PCI) in patients receiving standard anticoagulation therapy (hepa-
rin; purple bars) and in patients receiving no anticoagulation therapy (placebo;
hatched bars) (p  0.034).
In-Hospital and 30-Day MACE
Table 5 In-Hospital and 30-Day MACE
Control
No
Heparin
Death, n/total n (%)
In hospital 0 0
30 days 0 0
AMI, n/total n (%)
In hospital 11 (3.1) 6 (1.7)
30 days 11 (3.1) 7 (2)
ULR, n/total n (%)
In hospital 2 (0.6) 0 (0)
30 days 2 (0.6) 1 (0.3)
MACE, n/total n (%)
In hospital 13 (3.7) 6 (1.7)
30 days 13 (3.7) 7 (2)
AMI  acute myocardial infarction (3 times creatine kinase-myo
electrocardiography leads); CI  confidence interval; MACE  major aO
Cedian ACT value of 201  34 s could be achieved.
evertheless, neither guidewire or guiding catheter throm-
osis nor intraprocedural evidence of coronary thrombosis
ccurred in either of the groups.
The experience with wire thrombus in the OASIS (Op-
imal Antiplatelet Strategy for Interventions) trials but
one in this trial suggests that in a simple and elective
rocedure, the use of anticoagulation is not crucial. Of note,
he OASIS trial enrolled patients undergoing PCI for acute
oronary syndromes. This clinical condition sets the proce-
ures in a completely different thrombogenic milieu that
redisposes to catheter thrombosis; furthermore, not all
ASIS patients were taking aspirin and thienopyridines.
The minimal incidence of bleeding that occurred in this
tudy may be related to the fact that more than 95% of the
solute Risk
rence (95% CI) p Value for Superiority
(1.1% to 1.1%) 1.0
(1.1% to 1.1%) 1.0
(0.9% to 4.0%) 0.22
(1.3% to 3.8%) 0.34
(0.6% to 2.1%) 0.50
(1.1% to 1.8%) 1.0
(0.5% to 4.7%) 0.10
(0.1% to 4.5%) 0.17 (p for noninferiority 0.001)
band upper limits of normal or new Q waves in 2 contiguous
cardiac events; ULR  urgent lesion revascularization.
ncidence of Post-Procedural Bleeding
Table 6 Incidence of Post-Procedural Bleeding
Bleeding Control
No
Heparin
Absolute Risk
Difference (95% CI)
p Value for
Superiority
TIMI criteria (patients)
Number 346 348 — 0.69
Minor 4 2 0.6% (1.0% to 2.4%)
Major 0 0 0% (1.1% to 1.1%)
GUSTO criteria (patients)
Number 345 350 — 0.06
Mild 5 0 1.4% (0.1% to 3.3%)
Moderate 0 0 0 (1.1% to 1.1%)
Severe 0 0 0 (1.1% to 1.1%)
STEEPLE criteria (patients)
Number 344 350 — 0.048
Major 2 0 0.6% (0.6% to 2.1%)
Minor 4 0 1.1% (0.2 to 2.9%)
ACUITY criteria (patients)
Number 345 350 — 0.06
Major 5 0 1.4% (0.1% to 3.3%)
CUITY  Acute Catheterization and Urgent Intervention Triage Strategy Trial; CI  confidence
nterval; GUSTO  Global Utilization of Streptokinase and Tissue-Type Plasminogen Activator forAb
Diffe
0
0
1.4%
1.1%
0.6%
0.3%
2.0%
1.7%ccluded Coronary Arteries study; STEEPLE  Safety and Efficacy of Enoxaparin in Percutaneous
oronary Intervention Patients trial; TIMI  Thrombolysis In Myocardial Infarction study.
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Elective PCI Without Systemic Anticoagulation October 14, 2008:1293–8rocedures were conducted through a 5-F system (16).
leeding events were consistently lower in the group of
atients who did not receive systemic anticoagulation. Of
ote, all events were related to access site complication, and
one of them resulted in a surgical procedure or required
lood transfusion (17).
Our results are comparable with those reported in a registry
6) and a trial (7), in which the use of an adjunctive therapy
ased on aspirin, thienopyridine, and GPI without UFH
esulted in fewer bleeding complications and maintained effi-
acy in elective PCI. Of note, in our study, the use of a GPI
as left to operator discretion, but in no cases was a GPI used.
A meta-analysis suggested that there were increased isch-
mic complications among non-GPI patients undergoing PCI
ith lower ACTs (18). It has to be noted that all of our
atients underwent elective PCI to treat chronic coronary
rtery disease, whereas acute coronary syndromes represented a
ubstantial proportion of the meta-analysis population. The
hrombotic milieu of stable and unstable patients is substan-
ially different and justifies different levels of anticoagulation to
afely perform coronary interventions in these settings. Other
ifferences are related to procedural duration, in that1 h was
bserved in 27% of the meta-analysis cases (average procedural
ime was 11 min in our study), and to stent use, which was
estricted to bailout indications in the meta-analysis and was
andatory in our study.
A study limitation is intraprocedural use of heparinized
ush, which was not controlled for. However, given the
aximum amount allowed to be used, it is not likely to have
ignificantly affected activated clotting times.
onclusions
he CIAO (Coronary Interventions Antiplatelet-based Only)
rial is a single-center, double-blind, randomized study dem-
nstrating that elective PCI of simple coronary lesions in
atients pre-treated with double antiplatelet therapy is safe and
s associated with reduced bleeding events.
The concept tested, whether anticoagulation is necessary
or PCI if dual antiplatelet therapy is utilized, challenges a
asic assumption. However, this protocol was conducted
ith very simple elective procedures in a limited number of
elected patients, and this type of adjuvant treatment could
robably not be applied to all patients, even stable ones, and
ertainly not to patients with complex lesions in acute
oronary syndromes. Unless a large multicenter trial is
erformed that confirms these findings, this paper is not
ntended to provide false reassurance for an operator who
ecides to try this approach.
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